Your browser doesn't support javascript.
loading
A one-point increase in the Damage Index for Antiphospholipid Syndrome (DIAPS) predicts mortality in thrombotic antiphospholipid syndrome.
Gaspar, Pedro; Farinha, Filipa; Sayar, Zara; Efthymiou, Maria; Cohen, Hannah; Isenberg, David A.
Afiliação
  • Gaspar P; Department of Internal Medicine 2, North Lisbon University Hospital Centre, Lisbon, and Instituto de Medicina Molecular João Lobo Antunes, Faculty of Medicine, University of Lisbon, Portugal. pedrosilvagaspar@gmail.com.
  • Farinha F; Centre for Rheumatology, Division of Medicine, University College London, UK.
  • Sayar Z; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Efthymiou M; Haemostasis Research Unit, Department of Haematology, University College London, UK.
  • Cohen H; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, and Haemostasis Research Unit, Department of Haematology, University College London, UK.
  • Isenberg DA; Centre for Rheumatology, Division of Medicine, University College London, and Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, UK.
Clin Exp Rheumatol ; 41(3): 605-612, 2023 Mar.
Article em En | MEDLINE | ID: mdl-35819804
ABSTRACT

OBJECTIVES:

To determine whether early damage and its kinetics measured by the Damage Index for Antiphospholipid Syndrome (DIAPS) predicts mortality.

METHODS:

We carried out a single-centre retrospective analysis of thrombotic APS patients (2006 Sydney criteria), using the DIAPS for damage assessment. Early damage was considered to be at six months after disease onset; early damage increase (delta-DIAPS) was deemed to be at least a one-point rise in DIAPS within the first five years of illness. Groups were compared using appropriate statistical tests. Survival was analysed by the Kaplan-Meier method. Cox regression analysis was performed to investigate predictors of mortality.

RESULTS:

A total of 197 patients (71.1% female; 65.9% primary APS; 72.4% Caucasian) were followed for up to 43 years (median 10). Damage developed in 143 (73.6%) patients. Twenty-three patients (12%) died. Secondary APS (HR 3.07, 95%CI 1.32-7.12, p=0.009), male sex (HR 3.14, 95%CI 1.35-7.33, p=0.008) and age at APS onset ≥40 years (HR 5.34, 95%CI 1.96-14.53, p=0.001) were risk factors for death. Early damage (n=69, 35.0%) was not associated with death (p=0.231). Having a first arterial event was associated with early damage (p<0.001), but not with delta-DIAPS (p=0.539) nor with the risk of death (p=0.151). Delta-DIAPS (n=53/181, 29.3%) predicted mortality (HR 5.40, 95%CI 2.33-12.52, p<0.001), even after adjusting individually for APS category (secondary), sex (male), early damage and age at APS onset (≥40 years) (all p<0.005).

CONCLUSIONS:

Evolving damage in the first five years of illness, but not early damage, predicted mortality regardless of the nature of the first thrombotic event, sex, APS category and age.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Trombose / Síndrome Antifosfolipídica Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Trombose / Síndrome Antifosfolipídica Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article